Hi Dr T!
I just had a question regarding the trial design for the preclinical results released this morning.
It looks incredibly promising, particularly the sub therapeutic concentration response in high FTO expressing melanoma subtypes - however I saw a critique on another thread (albeit it is from a known troll on the forum) which I wanted to clarify (if possible/non price sensitive).
Is there a reason a control wasn’t used in the preclinica FTO melanoma trial? I couldn’t see mention of it (although please tell me if I have missed it!) and I’ve seen responses to this criticism suggesting that controls are not required in preclinicals.
I’ve looked online and every website I can find seems to suggest you do need a control group for a preclinical design, do you mind explaining why there wasn’t one with this trial (or letting me know if I’ve missed something)?
Thanks so much, and kudos to yourself and the entire RAC team!
General Comments / Chat, page-4104
-
- There are more pages in this discussion • 7,104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
-0.105(5.74%) |
Mkt cap ! $293.8M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.70 | $240.3K | 138.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 270 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |